Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nivolumab and Radiation vs Nivolumab and Ipilimumab in Adjuvant Merkel Cell Carcinoma
NCT03798639Phase 1Completed
- Start
- Jan 2019
- Primary completion
- Dec 2022
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial in Merkel cell carcinoma (MCC) comparing Arm I (nivolumab, radiation therapy) with Arm II (nivolumab, ipilimumab) (2 arms). Primary endpoint: Percentage of patients completing 12 months of treatment. Started Jan 2019; status: completed.
02
Drugs
nivolumabipilimumab
03
Conditions
Merkel cell carcinoma (MCC)
Beyond the preview
Go deeper on NCT03798639.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03798639.